Highly speculative even after the price has fallen

Frankfurt, Dusseldorf With a product against Covid-19 ready for series production, Novavax is about to make a breakthrough in the lucrative vaccine business. After deep red numbers in previous years, analysts are expecting net profits of around two billion dollars in the current year.

The reason for this is an active ingredient that does not use genetic engineering or live viruses. This could possibly convince many opponents of vaccination to protect themselves against Covid, so it is hoped.

The shares, which have fallen by almost 70 percent within a year, are still highly valued with a price/earnings ratio of 67 on the basis of the next twelve months. This makes the stock more vulnerable, especially on weak trading days.